Our 2 drugs in partnership with ISIS look good to pass with the second Antisense drug in our sub-field approved and heading to market.
Alicaforsen is in our field of reductors using antisense drugs and has passed the finish line… this is obviously another major endorsement and vote of confidence for our therapy type and application.
With only 5 drugs currently left in our sub category (2 being ours) we look more and more vulnerable imo. I wouldn’t be surprised if ISIS want a bigger chuck of ANP from here on as we are out to capture a multibillion dollar market so it’s no small change to anyone even them…
“An antisense drug that inhibits the production of a receptor protein, GHr. GHr reduces the level of a circulating hormone that has been shown to contribute to various diseases. Our partner, Antisense Therapeutics Limited, is developing ATL1103 for the treatment of acromegaly, a disease characterized by abnormal growth of organs”
Multibillions where our drug is far superior and undercuts competition by 50%
Follow the link and scroll down to our category…….
http://www.isispharm.com/Pipeline/index.htm
Good Luck!
ANP Price at posting:
8.0¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)